Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.

The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience ...

With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to ...

Ebglyss' approval highlights the opportunity that exists in the AD space, and may have potential advantages in efficacy and ...

Of the interviewed providers, 53.4% had experience with food allergy clinical trials, and 85% offered oral immunotherapy to ...

Topical delgocitinib appears more effective than oral alitretinoin and is comparable to dupilumab for treating types of hand eczema, according to two separate studies.

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

A group representing makers of compounded drugs sued FDA over its decision to call an end to the shortage of Lilly's (LLY) ...

Eli Lilly (NYSE:LLY) said it plans to take a Q3 acquired in-process research and development, or IPR&D, charge of ...

Democratic Vice President Kamala Harris led Republican Donald Trump by a marginal three percentage points - 46% to 43% - as the two remain locked in a close race to win the Nov. 5 U.S ...

The world’ smallest Rubik’ s cube launched weighing a mere of 0.33 grams hits the market with a staggering price of Rs.4.39 lakhs Japanese toy maker MegaHouse has created the world’s ...